Y-Intercept (HK)’s Myriad Genetics MYGN Stock Holding History

Y-Intercept (HK)’s Portfolio MYGN Stock Details MYGN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-654,224	Closed	-$2.94M	–	2014
2026 Q1	$2.94M	Buy	654,224 +297,331	+83%	+$1.55M	0.06%	537
2025 Q4	$2.19M	Buy	356,893 +171,827	+93%	+$1.25M	0.05%	587
2025 Q3	$1.34M	Buy	185,066 +81,064	+78%	+$481K	0.03%	831
2025 Q2	$552K	Sell	104,002 -8,982	-8%	-$53.1K	0.01%	1173
2025 Q1	$1M	Buy	112,984 +60,317	+115%	+$724K	0.07%	405
2024 Q4	$722K	Buy	52,667 +14,134	+37%	+$261K	0.05%	564
2024 Q3	$1.06M	Buy	38,533 +25,179	+189%	+$682K	0.06%	429
2024 Q2	$327K	Buy	+13,354	New	+$293K	0.02%	1001
2024 Q1	–	Sell	-20,905	Closed	-$400K	–	1625
2023 Q4	$400K	Buy	20,905 +1,357	+7%	+$23.5K	0.04%	705
2023 Q3	$314K	Buy	+19,548	New	+$372K	0.03%	752
2023 Q1	–	Sell	-40,706	Closed	-$591K	–	1415
2022 Q4	$591K	Buy	+40,706	New	+$758K	0.09%	372

Other funds holding MYGN

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

VPC

Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Y-Intercept (HK)'s MYGN Position: Q2 2026 in Review

Y-Intercept (HK) sold out of Myriad Genetics (MYGN) in Q2 2026, closing a stake of 654,224 shares — an estimated $2.94M sold.

Y-Intercept (HK) first reported a position in MYGN in Q4 2022 and held it in 11 quarters. The position peaked at $2.94M in Q1 2026. 197 funds tracked by Wall St. Rank hold MYGN as of Q2 2026.

Y-Intercept (HK) reported no remaining Myriad Genetics position as of Q2 2026 after selling out during the quarter.
Y-Intercept (HK) sold 654,224 Myriad Genetics shares in Q2 2026, an estimated $2.94M.
Y-Intercept (HK) first reported a position in Myriad Genetics in Q4 2022 and held it in 11 quarters.
Y-Intercept (HK)'s Myriad Genetics position peaked at $2.94M in Q1 2026.
197 funds tracked by Wall St. Rank held Myriad Genetics as of Q2 2026.

Based on Y-Intercept (HK)'s 13F filing for Q2 2026, filed 14 Jul 2026.